目的:本研究采用Meta分析方法,系统评估了COVID‐19患者外周血中TH1、TH2、TH17相关细胞因子水平,并深入探讨了这些细胞因子研究结果存在差异的原因。方法:本研究已通过国际荟萃分析INPLASY平台认证(INPLASY协议认证编号:202380023),通...目的:本研究采用Meta分析方法,系统评估了COVID‐19患者外周血中TH1、TH2、TH17相关细胞因子水平,并深入探讨了这些细胞因子研究结果存在差异的原因。方法:本研究已通过国际荟萃分析INPLASY平台认证(INPLASY协议认证编号:202380023),通过检索中国知网、PubMed、Embase、Cochrane和Web of Science数据库,收集COVID-19患者和健康对照群体外周血TH1、TH2、TH17相关细胞因子(TNF-a、IL-2、IL-4、IL-10、IL-17)水平的病例对照研究,检索时间范围为建库至2023年10月10日。由研究者独立完成文献筛选、数据提取和偏倚评估,使用RevMan 5.4软件进行Meta分析。结果:该Meta分析共检索出19,941项研究,最终纳入了6项进行Meta分析,这些研究均为中、高质量文献。患者入组的时间范围从2020年~2022年不等。结果表明:COVID-19感染组的患者外周血TNF-a水平显著高于健康对照组(HC组) [MD = 3.42, 95%CI (1.91, 4.92), I2 = 50%, P 2 = 98%, P = 0.0004];COVID-19感染组患者外周血IL-10水平显著高于健康对照组(HC组) [MD = 3.38, 95%CI (1.97, 4.80), I2 = 84%, P 2 = 98%, P = 0.009];COVID-19感染组患者与HC组外周血IL-2水平差异无统计学意义[MD = 0.89, 95%CI (−2.19, 3.97), I2 = 67%, P = 0.57]。结论:一些与TH1、TH2及TH17相关的细胞因子在COVID-19患者外周血中的水平明显高于健康对照组,这些细胞因子在新型冠状病毒感染的疾病进展中起着重要作用。Objective: In this study, we used Meta-analysis to systematically evaluate the levels of TH1, TH2, and TH17-related cytokines in the peripheral blood of COVID-19 patients, and the reasons for the differences in the findings of these cytokines were explored in depth. Methods: This study has been validated by the international Meta-analysis INPLASY platform (INPLASY protocol certification number: 202380023), by searching China Knowledge, PubMed, Embase, Cochrane and Web of Science databases, a case-control study on the levels of TH1, TH2, and TH17-related cytokines (TNFa, IL-2, IL-4, IL-10, and IL-17) in peripheral blood of COVID-19 patients and healthy control groups was collected, with a search timeframe from library construction to October 10, 2023. Literature screening, data extraction and bias assessment were done independently by the authors, and Meta-analysis was performed using RevMan 5.4 software. Results: The Meta-analysis retrieved a total of 19,941 studies, and 6 were finally included for Meta-analysis, which were all medium- and high-quality literature. The time of patient enrollment ranged from 2020 to 2022. The results showed that patients in the COVID-19-infected group had significantly higher peripheral blood TNF-a levels than in the healthy control group (HC group) [MD = 3.42, 95%CI (1.91, 4.92), I2 = 50%, P 2 = 98%, P = 0.0004];peripheral blood IL-10 levels were significantly higher in patients in the COVID-19-infected group than in the healthy control group (HC group) [MD = 3.38, 95%CI (1.97, 4.80), I2 = 84%, P 2 = 98%, P = 0.009];the difference in peripheral blood IL-2 levels between patients in the COVID-19-infected group and the HC group was not statistically significant [MD = 0.89, 95%CI (−2.19, 3.97), I2 =67%, P = 0.57]. Conclusion: Some cytokines related to TH1, TH2 and TH17 were significantly higher in the peripheral blood of COVID-19 patients than in the healthy control group, and these cytokines play an important role in the disease progression of novel coronavirus infections.展开更多
· AIM: To determine the effects of rapamycin on experimental autoimmune uveoretinitis(EAU) and investigate of role of rapamycin on T cell subsets in the disease.·METHODS: EAU was induced in rats using peptid...· AIM: To determine the effects of rapamycin on experimental autoimmune uveoretinitis(EAU) and investigate of role of rapamycin on T cell subsets in the disease.·METHODS: EAU was induced in rats using peptides1169 to 1191 of the interphotoreceptor binding protein(IRBP). Rapamycin(0.2 mg/kg/d) was administrated by intraperitoneal injection for a consecutive 7d after immunization. Th1/Th2/Th17 cytokines, TGF-β1, and IL-6produced by lymphocyteswere measured by ELISA, while Th17 cells and CD4 +CD25 + regulatory T cells(Tregs)from rat spleen were detected by flow cytometry.·RESULTS: Intraperitoneal treatment immediately after immunization dramatically ameliorated the clinical course of EAU. Clinical responses were associated with reduced retinal inflammatory cell infiltration and tissue destruction. Rapamycin induced suppression of Th1/Th2/Th17 cytokines, including IFN-γ, IL-2, IL-17, IL-4, and IL-10 release from T lymphocytes of EAU rats, in vitro.Rapamycin also significantly increased TGF-β1production but had no effect on IL-6 productionof T lymphocytes from EAU rats in vitro. Furthermore,rapamycin decreased the ratio of Th17 cells/CD4 +T cells and upregulated Tregs in EAU, as detected by flow cytometry.·CONCLUSION: Rapamycin effectively interferes with T cell mediated autoimmune uveitis by inhibiting antigen-specific T cell functions and enhancing Tregs in EAU.Rapamycin is a promising new alternative as an adjunct corticosteroid-sparing agent for treating uveitis.展开更多
目的研究旨在探讨痤疮合剂对辅助性T细胞(Helper T Cell,Th)1、Th2、Th17、调节性T细胞(Regulatory T cell,Treg)平衡的调节作用。方法除对照组,其他干预组用Kligman造模法制造兔耳痤疮模型2周,取病理,判断造模成功后,痤疮合剂组灌服痤...目的研究旨在探讨痤疮合剂对辅助性T细胞(Helper T Cell,Th)1、Th2、Th17、调节性T细胞(Regulatory T cell,Treg)平衡的调节作用。方法除对照组,其他干预组用Kligman造模法制造兔耳痤疮模型2周,取病理,判断造模成功后,痤疮合剂组灌服痤疮合剂17.52 g/(kg·d);阳性药物组灌服清热暗疮胶囊0.12 g/(kg·d);对照组及模型组灌服等量生理盐水,1次/d,共30 d。取静脉血及患处组织、耳根淋巴结,苏木精-伊红染色法(Hematoxylin-eosin staining,HE)检测毛囊面积和皮脂腺直径。酶联免疫吸附测定法(Enzyme linked immunosorbent assay,ELISA)检测血清中干扰素(Interferon,IFN)-γ、白介素(Interleukin,IL)-5、IL-17、IL-12、IL-22、IL-10、转化生长因子(Transforming growth factor,TGF)-β含量。蛋白质印迹法(Western blot)、免疫组织化学法检测耳根淋巴结中T盒转录因子(T-box expressed in T cell,T-bet)、GATA结合蛋白3(GATA binding protein 3,GATA3)、视黄酸受体相关孤儿核受体γt(Retineic-acid-receptor-related orphan nuclear receptor gamma,RORγt)、叉头盒转录因子p3(Forkhead box P3,Foxp3)表达水平。结果痤疮合剂能明显改善兔耳表皮层的结节、脓疱、组织厚度、囊肿及毛囊口扩张程度,减少炎症细胞的增殖和浸润,表皮和内壁角质层变薄松软。与对照组相比,其余各组IFN-γ、IL-12、IL-17、IL-22含量显著增高,IL-5、TGF-β、IL-10含量显著降低(P<0.01)。与模型组比较,痤疮合剂和阳性组IFN-γ、IL-17、IL-12、IL-22含量明显下降,IL-5、TGF-β、IL-10含量显著增高(P<0.01)。与对照组比较,其余各组T-bet、RORγt的表达及平均光密度值(Integral-Optimistically,IOD)显著增大,GATA3、Foxp3表达及IOD下降(P<0.01)。与模型组相比,痤疮合剂和阳性组T-bet、RORγt表达及IOD下调,GATA3、Foxp3表达及IOD上调(P<0.01)。结论痤疮合剂通过调控炎性因子平衡Th1/Th2、Th17/Treg的极化偏移,实现免疫细胞内稳态,改善皮损病理表现,对痤疮有明显的治疗效果。展开更多
文摘目的:本研究采用Meta分析方法,系统评估了COVID‐19患者外周血中TH1、TH2、TH17相关细胞因子水平,并深入探讨了这些细胞因子研究结果存在差异的原因。方法:本研究已通过国际荟萃分析INPLASY平台认证(INPLASY协议认证编号:202380023),通过检索中国知网、PubMed、Embase、Cochrane和Web of Science数据库,收集COVID-19患者和健康对照群体外周血TH1、TH2、TH17相关细胞因子(TNF-a、IL-2、IL-4、IL-10、IL-17)水平的病例对照研究,检索时间范围为建库至2023年10月10日。由研究者独立完成文献筛选、数据提取和偏倚评估,使用RevMan 5.4软件进行Meta分析。结果:该Meta分析共检索出19,941项研究,最终纳入了6项进行Meta分析,这些研究均为中、高质量文献。患者入组的时间范围从2020年~2022年不等。结果表明:COVID-19感染组的患者外周血TNF-a水平显著高于健康对照组(HC组) [MD = 3.42, 95%CI (1.91, 4.92), I2 = 50%, P 2 = 98%, P = 0.0004];COVID-19感染组患者外周血IL-10水平显著高于健康对照组(HC组) [MD = 3.38, 95%CI (1.97, 4.80), I2 = 84%, P 2 = 98%, P = 0.009];COVID-19感染组患者与HC组外周血IL-2水平差异无统计学意义[MD = 0.89, 95%CI (−2.19, 3.97), I2 = 67%, P = 0.57]。结论:一些与TH1、TH2及TH17相关的细胞因子在COVID-19患者外周血中的水平明显高于健康对照组,这些细胞因子在新型冠状病毒感染的疾病进展中起着重要作用。Objective: In this study, we used Meta-analysis to systematically evaluate the levels of TH1, TH2, and TH17-related cytokines in the peripheral blood of COVID-19 patients, and the reasons for the differences in the findings of these cytokines were explored in depth. Methods: This study has been validated by the international Meta-analysis INPLASY platform (INPLASY protocol certification number: 202380023), by searching China Knowledge, PubMed, Embase, Cochrane and Web of Science databases, a case-control study on the levels of TH1, TH2, and TH17-related cytokines (TNFa, IL-2, IL-4, IL-10, and IL-17) in peripheral blood of COVID-19 patients and healthy control groups was collected, with a search timeframe from library construction to October 10, 2023. Literature screening, data extraction and bias assessment were done independently by the authors, and Meta-analysis was performed using RevMan 5.4 software. Results: The Meta-analysis retrieved a total of 19,941 studies, and 6 were finally included for Meta-analysis, which were all medium- and high-quality literature. The time of patient enrollment ranged from 2020 to 2022. The results showed that patients in the COVID-19-infected group had significantly higher peripheral blood TNF-a levels than in the healthy control group (HC group) [MD = 3.42, 95%CI (1.91, 4.92), I2 = 50%, P 2 = 98%, P = 0.0004];peripheral blood IL-10 levels were significantly higher in patients in the COVID-19-infected group than in the healthy control group (HC group) [MD = 3.38, 95%CI (1.97, 4.80), I2 = 84%, P 2 = 98%, P = 0.009];the difference in peripheral blood IL-2 levels between patients in the COVID-19-infected group and the HC group was not statistically significant [MD = 0.89, 95%CI (−2.19, 3.97), I2 =67%, P = 0.57]. Conclusion: Some cytokines related to TH1, TH2 and TH17 were significantly higher in the peripheral blood of COVID-19 patients than in the healthy control group, and these cytokines play an important role in the disease progression of novel coronavirus infections.
基金Supported by National Natural Science Foundation of China(No.81371005)
文摘· AIM: To determine the effects of rapamycin on experimental autoimmune uveoretinitis(EAU) and investigate of role of rapamycin on T cell subsets in the disease.·METHODS: EAU was induced in rats using peptides1169 to 1191 of the interphotoreceptor binding protein(IRBP). Rapamycin(0.2 mg/kg/d) was administrated by intraperitoneal injection for a consecutive 7d after immunization. Th1/Th2/Th17 cytokines, TGF-β1, and IL-6produced by lymphocyteswere measured by ELISA, while Th17 cells and CD4 +CD25 + regulatory T cells(Tregs)from rat spleen were detected by flow cytometry.·RESULTS: Intraperitoneal treatment immediately after immunization dramatically ameliorated the clinical course of EAU. Clinical responses were associated with reduced retinal inflammatory cell infiltration and tissue destruction. Rapamycin induced suppression of Th1/Th2/Th17 cytokines, including IFN-γ, IL-2, IL-17, IL-4, and IL-10 release from T lymphocytes of EAU rats, in vitro.Rapamycin also significantly increased TGF-β1production but had no effect on IL-6 productionof T lymphocytes from EAU rats in vitro. Furthermore,rapamycin decreased the ratio of Th17 cells/CD4 +T cells and upregulated Tregs in EAU, as detected by flow cytometry.·CONCLUSION: Rapamycin effectively interferes with T cell mediated autoimmune uveitis by inhibiting antigen-specific T cell functions and enhancing Tregs in EAU.Rapamycin is a promising new alternative as an adjunct corticosteroid-sparing agent for treating uveitis.
